Treatment of One Case with Cryoglobulinaemia Secondary to Connective Tissue Disease with Small Doses of Rituximab.
West Indian Med J
; 65(2): 398-400, 2016 Apr 04.
Article
em En
| MEDLINE
| ID: mdl-28358454
OBJECTIVE: This study aims to observe the clinical efficacy of low-dose rituximab in patients with cryoglobulinaemia secondary to connective tissue diseases. METHODS: Rituximab (100 mg) was infused in patients once a week for four weeks, combined with prednisone (20 mg) once a day, and reduced regularly. Treatment effect was observed regularly. RESULTS: Joint pain, fever, rash and fatigue symptoms in patients eased. The serology (globulin, erythrocyte sedimentation rate, C-reactive protein, lactate dehydrogenase and others) parameters returned to normal. CONCLUSION: Low-dose rituximab therapy for cryoglobulinaemia secondary to connective tissue diseases was safe and effective, and can be used as a treatment option in this condition.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
West Indian Med J
Ano de publicação:
2016
Tipo de documento:
Article
País de afiliação:
China
País de publicação:
Jamaica